USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-1.11 | $-1.12 | $-0.97 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $53.68M | $47.55M | $36.89M |
Global Blood Therapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 21 | $-1.07 | $-1.42 | $-0.65 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 22 | $-4.50 | $-5.13 | $-3.92 |
| Dec 2022 | 21 | $-3.23 | $-5.01 | $0.11 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 1 / 1 | $-1.07 | $-1.07 | $-1.09 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 2 / 1 | $-4.51 | $-4.51 | $-4.60 |
| Dec 2022 | 1 / 0 | $-3.13 | $-3.13 | $-3.03 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 19 | $60.71M | $53.00M | $80.00M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 21 | $200.80M | $192.40M | $226.60M |
| Dec 2022 | 21 | $329.99M | $255.50M | $497.20M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $-1.11 | - | - |
| Aug 3, 2021 | Jun 2021 | $-1.18 | $-1.12 | 4.83% |
| May 5, 2021 | Mar 2021 | $-0.95 | $-1.21 | -27.10% |
| Feb 24, 2021 | Dec 2020 | $-0.97 | $-1.02 | -5.00% |
| Nov 5, 2020 | Sep 2020 | $-0.69 | $-0.97 | -41.50% |
| Aug 5, 2020 | Jun 2020 | $-1.14 | $-0.86 | 24.80% |
| May 6, 2020 | Mar 2020 | $-1.55 | $-1.20 | 22.75% |
| Feb 26, 2020 | Dec 2019 | $-1.23 | $-1.73 | -40.47% |
| Nov 7, 2019 | Sep 2019 | $-1.05 | $-1.07 | -1.52% |
| Aug 7, 2019 | Jun 2019 | $-0.96 | $-1.01 | -5.63% |
| May 8, 2019 | Mar 2019 | $-0.96 | $-0.87 | 9.55% |
| Feb 27, 2019 | Dec 2018 | $-0.89 | $-0.93 | -4.94% |
| Nov 6, 2018 | Sep 2018 | $-0.85 | $-0.83 | 2.42% |
| Aug 2, 2018 | Jun 2018 | $-0.87 | $-0.78 | 10.76% |
| May 7, 2018 | Mar 2018 | $-0.91 | $-0.87 | 4.05% |
| Feb 27, 2018 | Dec 2017 | $-0.72 | $-0.94 | -31.10% |
| Nov 2, 2017 | Sep 2017 | $-0.62 | $-0.66 | -7.09% |
| Aug 7, 2017 | Jun 2017 | $-0.61 | $-0.55 | 9.11% |
| May 1, 2017 | Mar 2017 | $-0.71 | $-0.60 | 15.78% |
| Mar 13, 2017 | Dec 2016 | $-0.64 | $-0.74 | -16.10% |
| Nov 9, 2016 | Sep 2016 | $-0.59 | $-0.58 | 2.36% |
| Aug 10, 2016 | Jun 2016 | $-0.63 | $-0.58 | 8.42% |
| May 12, 2016 | Mar 2016 | $-0.48 | $-0.56 | -15.87% |
| Mar 29, 2016 | Dec 2015 | $-0.43 | $-0.53 | -23.26% |
| Nov 12, 2015 | Sep 2015 | $-0.59 | $-0.90 | -52.54% |
| Aug 17, 2015 | Jun 2015 | $-2.39 | $-4.84 | -102.51% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 24, 2021 | Dec 2020 | $-3.99 | $-4.05 | - |
| Feb 26, 2020 | Dec 2019 | $-4.22 | $-4.68 | - |
| Feb 27, 2019 | Dec 2018 | $-3.37 | $-3.41 | - |
| Feb 27, 2018 | Dec 2017 | $-2.55 | $-2.75 | - |
| Mar 13, 2017 | Dec 2016 | - | $-2.46 | - |
| Mar 29, 2016 | Dec 2015 | - | $-6.27 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $53.68M | - | - |
| Aug 3, 2021 | Jun 2021 | $43.92M | $47.55M | 1.08% |
| May 5, 2021 | Mar 2021 | $43.00M | $39.04M | 0.91% |
| Feb 24, 2021 | Dec 2020 | $39.03M | $41.30M | 1.06% |
| Nov 5, 2020 | Sep 2020 | $43.98M | $36.89M | 0.84% |
| Aug 5, 2020 | Jun 2020 | $18.81M | $31.50M | 1.67% |
| May 6, 2020 | Mar 2020 | $3.66M | $14.12M | 3.86% |
| Feb 26, 2020 | Dec 2019 | $560.00K | $2.11M | 3.76% |
| Nov 7, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 7, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| May 8, 2019 | Mar 2019 | $0.00 | $0.00 | - |
| Feb 27, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Nov 6, 2018 | Sep 2018 | $0.00 | $0.00 | - |
| Aug 2, 2018 | Jun 2018 | $0.00 | $0.00 | - |
| May 7, 2018 | Mar 2018 | $0.00 | $0.00 | - |
| Feb 27, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Nov 2, 2017 | Sep 2017 | $0.00 | $0.00 | - |
| Aug 7, 2017 | Jun 2017 | $0.00 | $0.00 | - |
| May 1, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 13, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 9, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 10, 2016 | Jun 2016 | - | $0.00 | - |
| May 12, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 29, 2016 | Dec 2015 | - | $0.00 | - |
| Nov 12, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 17, 2015 | Jun 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 24, 2021 | Dec 2020 | $121.44M | $123.80M | 1.95% |
| Feb 26, 2020 | Dec 2019 | $490.00K | $2.11M | 330.20% |
| Feb 27, 2019 | Dec 2018 | $0.00 | $0.00 | - |
| Feb 27, 2018 | Dec 2017 | $0.00 | $0.00 | - |
| Mar 13, 2017 | Dec 2016 | - | $0.00 | - |
| Mar 29, 2016 | Dec 2015 | - | $0.00 | - |
GBT's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 21 analysts, the average EPS estimation for Global Blood Therapeutics's next quarterly earnings is $-1.11, with a low EPS estimation of $-1.38, and a high estimation of $-0.94.
Over the last 1 month, EPS estimates have seen 2 upward revisions and 0 downward. The EPS 1 month trend is $-1.11, the last 2 month trend is $-1.11, and the 3 month trend is $-1.13.
Based on 18 analysts, the average revenue estimation is $53.68M, with a low revenue estimation of $51.90M, and a high estimation of $60.00M.
Global Blood Therapeutics's previous earnings date was Aug 3, 2021 for its fiscal quarter ended Jun 30, 2021.
GBT's earnings per share (EPS) was $-1.12, beating the consensus analysts forecast of $-1.18 by 4.83%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -7.44%, and lower than the same period a year before (Jun 2020) by 30.23%.
Revenues were $47.55M, better than the forecast of $43.92M by 8.28%, up by 21.80% from the previous quarter , and up by 50.96% from the same period last year.
The company reported a net income of $-69.59M.Free cash flow for the quarter was $-45.11M , compared to $-80.39M last quarter and $-48.88M a year before.
GBT ended the quarter with $230.95M in total debt, a decrease of -0.43% compared to the previous quarter, and an increase of 0.51% compared to the same quarter a year before.
Global Blood Therapeutics's previous annual earnings date was Feb 24, 2021 for its fiscal year ended Dec 31, 2020.
GBT's earnings per share (EPS) was $-4.05, missing the consensus analysts forecast of $-3.99 by 1.38% , and higher than the previous year's EPS (Dec 2019) by -13.52%.
Revenues were $123.80M, better than the forecast of $121.44M by 1.95%, and up by 5773.01% from previous year's revenue.
The company reported a net income of $-247.55M.
Global Blood Therapeutics reported a free cash flow of $-220.62M for its fiscal year, compared to $-197.88M a year ago.
The company ended the fiscal year with $153.65M in total debt, an increase of 103.71% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
